Check Cap (MBAI) Akcija Kursas

Check Cap Kursas

NASDAQ·UŽDARTAS
3,25
​
Rinka uždaryta

Check Cap akcijos kaina

Gaukite šiuos duomenis per Eulerpool API

Check Cap akcija ir akcijų analizė

„Check Cap Ltd“ yra tarptautinė biotechnologijų įmonė, specializuojasi neinvazinių diagnostikos technologijų, skirtų ankstyvai storoji žarnos vėžio detekcijai, plėtroje. Įmonės būstinė įsikūrusi Izraelyje, o ji buvo įkurta 2004 metais.

Dažnai užduodami klausimai apie Check Cap akciją

The business model of Check Cap Ltd is focused on developing and commercializing an ingestible capsule system for colorectal cancer screenings. This innovative technology, known as the C-Scan, utilizes ultra-low dose X-ray technology to generate 3D images of the colon. By providing a non-invasive and patient-friendly alternative to traditional colonoscopies, Check Cap aims to increase the accessibility and early detection of colorectal cancer. This approach holds great potential in improving global healthcare outcomes and reducing healthcare costs associated with colorectal cancer screenings. As a leader in medical imaging technology, Check Cap Ltd is committed to driving advancements in the field of gastroenterology and revolutionizing cancer diagnostics.

Check Cap Ltd is primarily active in the healthcare industry, specifically in the field of medical diagnostics.

The main competitors of Check Cap Ltd in the market include companies such as Exact Sciences Corporation, Cerner Corporation, and Medtronic plc.

Check Cap Ltd is a pioneering medical technology company founded in 2004. The company focuses on the development of innovative capsule-based solutions for the medical imaging industry. Check Cap Ltd specializes in developing the C-Scan® system, a patient-friendly device designed to detect colorectal polyps and other gastrointestinal abnormalities. With cutting-edge imaging technology and a commitment to improving patient care, Check Cap Ltd has become a leading player in the medical imaging industry. Known for its dedication to innovation and its focus on improving diagnostic procedures, Check Cap Ltd continues to make significant advancements in the field of gastrointestinal imaging.

Check Cap Ltd has achieved several significant milestones in its journey. Some notable achievements include the successful completion of clinical trials for its C-Scan system, which is a revolutionary ingestible capsule for colorectal cancer screening. The company has also obtained CE Mark approval for the C-Scan system, allowing it to be marketed and sold in Europe. In addition, Check Cap Ltd has entered into partnerships and collaborations with renowned healthcare institutions and industry leaders, further enhancing its position in the market. These milestones highlight Check Cap Ltd's commitment to developing innovative solutions for early detection and prevention of colorectal cancer.

Check Cap Ltd is primarily present in Israel, the United States, and Europe.

Check Cap Ltd is committed to upholding strong values and a clear corporate philosophy. As a company specializing in medical diagnostics, Check Cap prioritizes integrity, innovation, and excellence in its operations. By developing cutting-edge technologies, Check Cap aims to revolutionize the field of screening and early detection of colorectal cancer. The company's core philosophy revolves around patient care, providing non-invasive solutions for effective diagnosis. Check Cap Ltd strives to foster an environment of trust, transparency, and social responsibility, driving its commitment to improving healthcare outcomes and enhancing patients' lives.

6 analitikai šiuo metu vertina Check Cap akciją: 0 rekomenduoja pirkti, 3 laikyti ir 3 parduoti. 2026 m. analitikai tikisi, kad Check Cap gaus 4,76 mln. USD pajamų ir −0,16 USD pelno akcijai.

Pagal dabartinį kursą Check Cap akcija kainuoja 2,91 EUR (3,25 USD).

Check Cap akcija (MBAI) kotiruojama 3 biržose, įskaitant: NASDAQ (CHEK), Frankfurt (7CC.F), München (7CC.MU).

Check Cap Ltd is a research-based medical technology company based in Israel. It develops products for the prevention, diagnosis, and monitoring of gastroenterological diseases, with its core product being the C-Scan®. The C-Scan® is a non-invasive, capsule-based technology that allows for the scanning of the entire digestive tract to detect potential tumors or other abnormalities early on. It offers an alternative to traditional colonoscopies and improves diagnostic accuracy. The C-Scan® is easy to use, painless, and requires no prior preparation or cleaning of the colon. Check Cap also conducts clinical studies to develop and test medications for gastroenterological diseases and works on new technologies for better visualization of the digestive tract. Its business model combines research and development, clinical studies, product development, and partnerships with other companies and institutions. With its innovative technology, Check Cap has the potential to change the way gastroenterological diseases are diagnosed, treated, and monitored.

tikėtina pelnas Check Cap yra 4,76 mln. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.

tikėtina grynasis pelnas Check Cap yra −145 800,00 USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.

Kainų ir nuomos santykis (KGV) Check Cap šiuo metu yra −19,85. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Check Cap akcijos vertę.

Kainų ir pardavimų santykis (KUV) Check Cap šiuo metu yra 0,61. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Check Cap akcijos įvertinimo metrika.

Eulerpool kokybės balas Check Cap yra 2/10.

Check Cap ISIN yra IL0011336851. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.

Check Cap WKN yra A14QUF. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.

Check Cap prekybos žymė yra MBAI. Ši biržos žymė naudojama Check Cap akcijoms prekiauti biržoje.

Tikroji vertėTerminal
3,05 USD
Per/Nepakankamai vertintaTerminal
Teisingai vertinta
Sektorius
Industrija
Sveikatos priežiūros įranga ir pasiūla
Akcijų skaičius
Darbuotojai
Pajamų augimas Ø5 metai
EBIT augimas Ø5 metai
Grynojo pelno augimas Ø5 metai
Svetainė check-cap.com
Šalis
Izraelis
Valiuta
USD
Pirminis viešas pasiūlymas
2015-02-19
ISIN
IL0011336851
CUSIP
M2361E203
SEDOL
BVTGHG0
Rinkos kapitalizacija
52 savaičių diapazonas
AAQS
3 / 10
PEG
—
P/E santykis
K/P santykise 2026
−19,85
K/P santykise 2027
—
P/S
K/A santykise
0,61
EV/EBIT
—
P/B santykis
6,89
ROE (nuosavo kapitalo grąža)
ROA (turto grąža)
ROCE (grąža iš panaudoto kapitalo)
ROIC (grąža iš investuoto kapitalo)
119,90 %
Paskutinį kartą atnaujinta 2026-10-13 02:08

Check Cap Pagrindiniai konkurentai

Check Cap Biržos simbolis

FRANKFURTAS · 7CC.FMIUNCHENAS · 7CC.MUNASDAQ · CHEK

Check Cap FIGI

CHEK:US · BBG0089RJVS4CHEK:UA · BBG0089RJVT3CHEK:UC · BBG0089RJVV0CHEK:UN · BBG0089RJVX8CHEK:UP · BBG0089RJVY7CHEK:UB · BBG0089RJW02CHEK:UM · BBG0089RJW20CHEK:UX · BBG0089RJW39CHEK:UR · BBG0089RJW48CHEK:UD · BBG0089RJW93CHEK:UF · BBG0089RJWD8CHEK:VY · BBG0089RJWF6

Visos Check Cap pagrindinės charakteristikos ir giluminė analizė

Mūsų akcijų analizė Check Cap akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Check Cap. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: